Laboratory evaluation of new antifungal agents against rare and refractory mycoses

Current Opinion in Infectious Diseases

Volumn 15, Issue 6, 2002, Pages 575-582

  Sutton, Deanna A ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Caspofungun; In vitro antifungal susceptibility; New antifungal agents; Posaconazole; Ravuconazole; Refractory mycoses; Voriconazole

Indexed keywords

1 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 3 [4 (1H TETRAZOL 1 YL)PHENYL] 2 IMIDAZOLIDINONE; 4 [4 [5 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4, TRIAZOL 1 YL)PROPYLTHIO] 1,3 DIOXAN 2 YL] 1,3 BUTADIENYL] 3 FLUOROBENZONITIRLE; ALBACONAZOLE; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; NEW DRUG; POSACONAZOLE; RAVUCONAZOLE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SORDARIN DERIVATIVE; SULFANILAMIDE DERIVATIVE; TERBINAFINE; TETRACYCLINE DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; BLASTOMYCOSIS; CANDIDA; CANDIDIASIS; CRYPTOCOCCUS NEOFORMANS; FUSARIUM; HISTOPLASMOSIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; MYCOSIS; NONHUMAN; REVIEW; SCEDOSPORIUM; TRICHOSPORON; YEAST;

EID: 0036910953     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200212000-00004     Document Type: Review

References (91)

1. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001; 33:641-647.
2. Ascioglu S, Rex JH, DePauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34:7-14. This paper describes the first standard definitions for invasive fungal infections in immunocompromised patients for use in clinical and epidemiological research.
3. Patterson TF. Invasive mycoses: Management and unmet medical needs. Curr Opin Infect Dis 2001; 14:669-671.
4. Revankar SG, Patterson JE, Sutton DA, et al. Disseminated phaeohyphomycosis: Review of an emerging mycosis. Clin Infect Dis 2002; 34:467-476. A thorough review of risk factors for and etiologic agents inciting disseminated phaeohyphomycosis.
5. Redding SW. The role of yeasts other than Candida albicans in oropharyngeal candidiasis. Curr Opin Infect Dis 2001; 14:673-677. Discusses the emergence of yeasts other than C. albicans as agents of oropharyngeal candidiasis in at-risk patients.
6. Cimon B, Carrère J, Vinatier JF, et al. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2000; 19:53-56.
7. Idigoras P, Pérez-Trallero E, Pineiro L, et al. Disseminated infection and colonization by Scedosporium prolificans: A review of 18 cases, 1990-1999. Clin Infect Dis 2001; 32:158-165. Risk factors, therapy, outcomes, and in-vitro data are reviewed for this extremely refractory mycosis.
8. Kuhn DM, George T, Chandra J, et al. Antifungal susceptibility of Candida biofilms: Unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46:1773-1780. Confirms dramatically reduced susceptibility of Candida biofilms to antifungal agents while presenting data to illustrate good activity by lipid formulations of amphotericin B and the echinocandins.
9. Pfaller MA, Yu WL. Antifungal susceptibility testing. Infect Dis Clin North Am 2001; 15:1227-1261. A major review of the current status of antifungal susceptibility testing including methods, utility in surveillance and new drug evaluation, clinical applications, MIC interpretative breakpoints, and recommendation for clinical laboratories.
10. Bernal S, Aller AI, Chávez M, et al. Comparison of the Sensititre YeastOne colorimetric microdilution panel and the NCCLS broth microdilution method for antifungal susceptibility testing against Candida species. Chemotherapy 2002; 48:21-25
11. Pfaller MA, Diekema DJ, Messer SA, et al. Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents including the new triazoles posaconazole, ravuconazole, and voriconazole. J Clin Microbiol 2002; 40:1694-1697. Provides evidence for the use of commercially prepared frozen microtiter panels that produce results in agreement with the M27-A NCCLS reference method.
12. Cuenca-Estrella M, Díaz-Guerra TM, Mellado E, Rodríguez-Tudela JL. Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp. J Clin Microbiol 2001; 39:525-532.
13. Kronvall G, Karlsson I. Fluconazole and voriconazole multidisk testing of Candida species for disk test calibration and MIC estimation. J Clin Microbiol 2001; 39:1422-1428.
14. Barry AL, Pfaller MA, Rennie RP, et al. Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods. Antimicrob Agents Chemother 2002; 46:1781-1784.
15. Wenisch C, Moore CB, Krause R, et al. Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome. J Clin Microbiol 2001; 39:2458-2462.
16. Hadley S, Martinez JA, McDermott L, et al. Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients. J Antimicrob Chemother 2002; 49:415-419. Authors describe real-time management of eight patients experiencing invasive mycoses by use of a two or three-tube semi-solid agar-tube method for MIC determination, and show retrospective correlation with the NCCLS reference method.
17. Arthington-Skaggs BA, Jradi H, Desal T, Morrison CJ. Quantitation of ergosterol content: Novel method for determination of fluconazole susceptibility of Candida albicans. J Clin Microbiol 1999; 37:3332-3337.
18. Lewis RE, Diekema DJ, Messer SA, et al. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother 2002; 49:345-351. Interesting report on the potential utility of time-kill studies and the Etest for synergy testing against Candida species.
19. Petrikkou E, Rodríguez-Tudela, Cuenca-Estrella M, et al. Inoculum standardization for antifungal susceptibility testing of filamentous fungi pathogenic for humans. J Clin Microbiol 2001; 39:1345-1347.
20. Espinel-Ingroff A. Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole. Antimicrob Agents Chemother 2001; 45:605-607.
21. Espinel-Ingroff A, Bartlett M, Chaturvedi V, et al. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. Antimicrob Agents Chemother 2001; 45:1828-1835. An eight-laboratory study to define the most appropriate parameters for use with the M38-P document to detect azole resistance in Aspergillus species.
22. Espinel-Ingroff A, Rezusta A. E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: Comparison with NCCLS broth microdilution method. J Clin Microbiol 2002; 40:2101-2107. Describes potential utility of the Etest for the determination of in-vitro Aspergillus susceptibility data.
23. Espinel-Ingroff A. Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi. J Clin Microbiol 2001; 39:1360-1367.
24. Hawser SP, Jessup C, Vitullo J, Ghannoum MA. Utility of 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl-amino) carbonyl]-2H-tetrazolium hydroxide and minimum effective concentration assays in the determination of antifungal susceptibility of Aspergillus fumigatus to the lipopeptide class of compounds. J Clin Microbiol 2001; 39:2738-2741.
25. Meletiadis J, Mouton JW, Meis JFGM, et al. Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis {2-methoxy-4-nitro-5[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide}, for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 2001; 39:4256-4263.
26. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2001; 45:327-330. Describes the minimum effective concentration endpoint for use with echinocandin susceptibility testing.
27. Te Dorsthorst DTA, Verweij PE, Meis JFGM, et al. Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals against itraconazole-susceptible and -resistant Aspergillus fumigatus isolates. Antimicrob Agents Chemother 2002; 46:702-707. With increased interest in combination therapies, this paper compares standard methods of synergy testing with response surface modeling for in-vitro interactions.
28. Fernández-Torres B, Pereiro Jr M, Guarro J. Comparison of two methods for antifungal susceptibility testing of Trichophyton rubrum. Eur J Clin Microbiol Infect Dis 2002; 21:70-71.
29. Arathoon EG. Clinical efficacy of echinocandin antifungals. Curr Opin Infect Dis 2001; 14:685-691. Nice review of approved and investigational echinocandin antifungal agents.
30. Pound MW, Drew RH, Perfect JR. Recent advances in the epidemiology, prevention, diagnosis, and treatment of fungal pneumonia. Curr Opin Infect Dis 2002; 15:183-194.
31. Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet 2002; 359:1135-1144. Excellent paper categorizing approved and investigational drugs by trade names, dosage, mechanism of action, spectrum of activity, and mechanisms of resistance for the major agents of refractory mycoses.
32. Maschmeyer G. New antifungal agents: Treatment standards are beginning to grow old. J Antimicrob Chemother 2002; 49:239-241.
33. Arikan S, Rex JH. New agents for treatment of systemic fungal infections. Expert Opin Emerg Drugs 2000; 5:135-160.
34. phox-/- knockout mice. Antimicrob Agents Chemother 2002; 46:1240-1245.
35. Petraitiene R, Petraitis V, Gross AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: Pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46:12-23. Large study on the efficacy, pharmacokinetics, and safety of caspofungin in the treatment and phophylaxis of invasive pulmonary aspergillosis in a persistently neutropenic mouse model.
36. Safdar A. Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus: Rapid response to treatment with caspofungin and itraconazole. Clin Infect Dis 2002; 34:1415-1417.
37. Gonzalea GM, Tijerina R, Najvar LK, et al. Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother 2001; 45:1854-1859.
38. Bachmann SP, Patterson TF, López-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol 2002; 40:2228-2230. Describes the clinical utility of caspofungin in the therapy of azole-resistant C. albicans.
39. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46:245-247.
40. Verweij PE, van den Bergh MFQ, Rath PM, et al. Invasive aspergillosis caused by Aspergillus ustus: Case report and review. J Clin Microbiol 1999; 37:1616-1619.
41. Verweij PE, Te Dorsthorst DTA, Rijs AJMM, et al. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J Clin Microbiol 2002; 40:2648-2650.
42. Mosquera J, Denning DW. Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2002; 46:556-557.
43. Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: Report from SENTRY antimicrobial surveillance program, 2000. Antimicrob Agents Chemother 2002; 46:1032-1037. Major surveillance study compiling in-vitro data for approved and investigational triazoles against Aspergillus spp. and other filamentous fungi.
44. Revankar SG, Sutton DA, Sanche SE, et al. Metarrhizium anisopliae as a cause of sinusitis in immunocompetent hosts. J Clin Microbiol 1999; 37:195-198.
45. Sun QN, Fothergill AW, McCarthy DI, et al. In vitro activities of posaconazole, itraconazole, voriconazofe, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46:1581-1582. Describes the potential clinical utility of posaconazole in the therapy of zygomycosis.
46. Gonzales GM, Sutton DA, Thompson E, et al. In vitro activities of approved and investigational antifungal agents against 44 clinical isolates of basidiomycetous fungi. Antimicrob Agents Chemother 2001; 45:633-635.
47. Sutton DA, Sanche SE, Revankar SJ, et al. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 1999; 37:2343-2345.
48. Silveira F, Nucci M. Emergence of black moulds in fungal disease: Epidemiology and therapy. Curr Opin Infect Dis 2001; 14:679-684.
49. Espinel-Ingroff, A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39:954-958.
50. Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001; 39:3254-3259.
51. Ernst EJ, Yodoi K, Roling EE, Klepser ME. Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods. Antimicrob Agents Chemother 2002; 46:578-581. Presents evidence that amphotericin B demonstrates considerable in-vitro activity against C. lusitaniae, even when the MICs are elevated.
52. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, et al. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother 2002; 46:1144-1146. Authors provide in-vitro data suggesting clinical efficacy of the new triazoles against amphotericin B-refractory Trichosporon spp.
53. Pfaller MA, Messer SA, Hollis RJ, et al. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agent Chemother 2002; 46:1723-1727. Major surveillance study indicating superiority of both voriconazole and ravuconazole over currently available agents for Candida spp., and their excellent activity against C. krusei.
54. Pfaller MA, Diekema DJ, Jones RN, et al. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY antimicrobial surveillance program, 1997 to 2000. J Clin Microbiol 2002; 40:852-8567. Study demonstrates differences in investigational triazole MICs against bloodstream Candida isolates relative to pediatric and adult age groups.
55. Perea S, Fothergill AW, Sutton DA, et al. Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method. J Clin Microbiol 2001; 39:385-388.
56. Sugar AM, Liu X. Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrob Agents Chemother 2001; 45:601-604.
57. Lass-Flörl C, Nagl M, Speth C, et al. Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining. Antimicrob Agents Chemother 2001; 45:124-128.
58. Fernández-Torres B, Carrillo AJ, Martín E, et al. In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob Agents Chemother 2001; 45:2524-2528. Provides in-vitro documentation of MIC differences for various species of dermatophytes against 10 antifungal agents.
59. Groll AH, Mickiene D, Petraitiene R, et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): Reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2001; 45:2845-2855. Major paper for a thorough understanding of the pharmacokinetic/pharmacodynamics of anidulafungin in neutropenic animal models for disseminated candidiasis and pulmonary aspergillosis.
60. Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistent neutropenic rabbits. Antimicrob Agents Chemother 2002; 46:1857-1869. Major paper for a thorough understanding of the pharmacokinetic/pharmacodynamics of micafungin in neutropenic animal models for disseminated candidiasis and pulmonary aspergillosis.
61. Müller F-MC, Kurzai O, Hacker J, et al. Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis. J Antimicrob Chemother 2001; 48:713-715.
62. Gonzales GM, Tijerina R, Najvar LK, et al. In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrob Agents Chemother 2002; 46:1352-1356. Documents potent in-vivo/in-vitro activity of posaconazole against Coccidioides immitis.
63. Pfaller MA, Messer SA, Hollis RJ, Jones RN. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001; 45:2862-2864. Large-scale surveillance study indicating the excellent activity of posaconazole against all species of Candida, excluding C. glabrata.
64. Barchiesi F, Daniela A, Vamiletti V, et al. In vitro activity of posaconazole against clinical isolates of dermatophytes. J Clin Microbiol 2001; 39:4208-4209. Suggests potential clinical utility of posazonazole equal to that of itrazonazole against dermatophytoses, with possible superiority against Microsporon species.
65. Sun QN, Najar LK, Bocanegra R, et al. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 2002; 46:2310-2312. An animal study suggesting the potential utility of posaconazole in the therapy of zygomycosis due to Mucor species.
66. Barchiesi F, Schimizzi AM, Najvar LK, et al. Interactions of posaconazole and flucytosine against Cryptococcus neoformans. Antimicrob Agents Chemother 2001; 45:1355-1359.
67. Barchiesi, F, Schimizzi AM, Caselli F, et al. Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J Antimicrob Chemother 2001; 31:769-773. A murine model demonstrating superior activity of posaconazole over amphotericin B in reducing the fungal burden in the brain.
68. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: Correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001; 45:857-869.
69. Mikamo H, Yin XH, Hayasaki Y, et al. Penetration of ravuconazole a new triazole antifungal, into rat tissues. Chemotherapy 2002; 48:7-9.
70. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. J Antimicrob Chemother 2002; 49:353-357.
71. Clemons KV, Stevens DA. Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice. Antimicrob Agents Chemother 2001; 45:3433-3436.
72. Clemons KV, Martinez M, Calderon L, Stevens DA. Efficacy of ravuconazole in treatment of systemic murine histoplasmosis. Antimicrobial Agents Chemother 2002; 46:922-924.
73. Tsuchimori N, Hayashi R, Kitamoto N, et al. In vitro and in vivo antifungal activities of TAK-456, a novel oral triazole with a broad antifungal spectrum. Antimicrob Agents Chemother 2002; 46:1388-1393.
74. Kamai Y, Harasaki T, Fukuoka T, et al. In vitro and in vivo activities of CS-758 (R-120758), a new triazole antifungal agent. Antimicrob Agents Chemother 2002; 46:367-370.
75. Lass-Flörl C, Dierich MP, Fuchs D, et al. Antifungal properties of selective serotonin reuptake inhibitors against Aspergillus species in vitro. J Antimicrob Chemother 2001; 48:775-779.
76. Lass-Flörl C, Dierich MP, Fuchs D, et al. Antifungal activity against Candida species of the selective serotonin-reuptake inhibitor, sertraline. Clin Infect Dis 2001; 33:135-136.
77. Deresinski SC. Coccidioidomycosis: Efficacy of new agents and future prospects. Curr Opin Infect Dis 2001; 14:693-696.
78. Afeltra J, Meis JFGM, Vitale RG, et al. In vitro activities of pentamidine, pyrimethamine, trimethoprim, and sulfonamides against Aspergillus species. Antimicrob Agents Chemother 2002; 46:2029-2031. Interesting paper suggesting possible utility of sulfa drugs in the therapy of aspergillosis.
79. Liu Y, Ryan ME, Lee H-M, et al. A chemically modified tetracycline (CMT-3) is a new antifungal agent. Antimicrob Agents Chemother 2002; 46:1447-1454. Describes unexpected antifungal properties of chemically modified tetracyclines.
80. Liu Y, Tortora G, Ryan ME, et al. Potato dextrose agar antifungal susceptibility testing for yeasts and molds: Evaluation of phosphate effect on antifungal activity of CMT-3. Antimicrob Agents Chemother 2002; 46:1455-1461.
81. Meletiadis J, Mouton JW, Rodreques-Tudela JL, et al. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob Agents Chemother 2000; 44:470-472.
82. Weig M, Müller F-MC. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2001; 45:966-968.
83. Perea S, Gonzales G, Fothergill AW, et al. In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles. J Clin Microbiol 2002; 40:1831-1833. Describes potential use of terbinafine/triazole combination therapy for C. glabrata.
84. Meletiadis J, Meis JFGM, Mouton JW, et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002; 46:62-68. Provides a comprehensive review of polyene and triazole in-vitro data against Scedosporium species.
85. Redding SW, Kirkpatrick WR, Coco BJ, et al. Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer. J Clin Microbiol 2002; 40:1879-1881. Describes first three patients with oropharyngeal candidiasis caused by C. glabrata.
86. Rodero L, Cuenca-Estrella M, Córdoba A, et al. Transient fungemia caused by an amphotericin B-resistant isolate of Candida haemulonii. J Clin Microbiol 2002; 40:2266-2269. Documents the emergence of another amphotericin B-resistant yeast.
87. Wolf DG, Falk R, Hachan M, et al. Multidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care units. J Clin Microbiol 2001; 39:4420-4425.
88. Guarro J, Aguilar C, Pujol I. In vitro antifungal susceptibilities of Basidiobolus and Conidiobolus spp. strains. J Antimicrob Chemother 1999; 44:557-560.
89. Carillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001; 45:2151-2153. Suggests potential clinical utility of voriconazole and UR-9825 for the therapy of Scedosporium prolificans infections.
90. Gil-Lamaignere C, Roilides E, Josquera J, et al. Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob Agents Chemother 2002; 46:2234-2237. Authors describe the addition of human polymorphonuclear leukocytes to potentiate the activity of triazoles for the therapy of scedosporiosis.
91. Furukawa H, Kusne S, Sutton DA, et al. Acute invasive sinusitis due to Trichoderma longibrachiatum in a liver and small bowel transplant recipient. Clin Infect Dis 1998; 26:487-489.